Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexus Surgical and MedicareBOM:538874 -0.67%82 EBITDA Margin % is 14.54% as of Mar. 2026, which is 96% above its 10-year median of 7.40. GuruFocus rates BOM:538874 with a GF Score™ of 82/100 and a GF Value™ of ₹33.71 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, Nexus Surgical and Medicare ranks better than 83.19% on this metric.
Nexus Surgical and Medicare (BOM:538874) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nexus Surgical and Medicare EBITDA Margin % Related Terms
Nexus Surgical and Medicare EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538874 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Nexus Surgical and Medicare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexus Surgical and Medicare EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Nexus Surgical and Medicare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nexus Surgical and Medicare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexus Surgical and Medicare (BOM:538874) has a EBITDA Margin % of 14.54% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nexus Surgical and Medicare and its competitors. This is 96% above median its historical median of 7.40. According to the industry distribution chart, Nexus Surgical and Medicare ranks #20 out of 119 companies in the Medical Distribution industry, placing it in the top 16.8%.
Is Nexus Surgical and Medicare's EBITDA Margin % too high?
Nexus Surgical and Medicare's current EBITDA Margin % of 14.54% is 96% above median its 10-year median of 7.40. The Medical Distribution industry median EBITDA Margin % is 4.11. Nexus Surgical and Medicare's value of 14.54% is 253.8% above this industry median. Based on the distribution chart, Nexus Surgical and Medicare ranks #20 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Nexus Surgical and Medicare has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nexus Surgical and Medicare's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Nexus Surgical and Medicare ranks #20 out of 119 companies for EBITDA Margin %. This places Nexus Surgical and Medicare in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.11. Nexus Surgical and Medicare's value of 14.54% is 253.8% above this benchmark. While the company's 10-year median is 7.40 vs. the industry median of 4.11, Nexus Surgical and Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.11, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexus Surgical and Medicare's current EBITDA Margin % of 14.54% is 253.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nexus Surgical and Medicare and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexus Surgical and Medicare's current EBITDA Margin % is 14.54%, which is 96% above median its own 10-year median of 7.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexus Surgical and Medicare stock overvalued right now?
Based on GuruFocus' analysis, Nexus Surgical and Medicare (BOM:538874) is currently considered Possible Value Trap. The stock's GF Value™ is ₹33.71, compared to a current price of ₹19.15 — trading 43.2% below its estimated fair value. The current EBITDA Margin % is 14.54%, which is 96% above median its 10-year median of 7.40 and 253.8% above the Medical Distribution industry median of 4.11. Nexus Surgical and Medicare's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nexus Surgical and Medicare (BOM:538874), the current EBITDA Margin % is 14.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexus Surgical and Medicare (BOM:538874) Overvalued in 2026?
Based on GuruFocus' analysis, Nexus Surgical and Medicare stock appears to be undervalued.
The current stock price of ₹19.15 is trading 43.2% below its estimated GF Value™ of ₹33.71.
GuruFocus considers Nexus Surgical and Medicare to be Possible Value Trap.
Key valuation signals for BOM:538874:
EBITDA Margin %: 14.54% (96% above median its 10-year median of 7.40)
GF Value™: ₹33.71 vs. price of ₹19.15 (43.2% below fair value)
Industry Position: 253.8% above the Medical Distribution median (#20 of 119)
No single metric tells the full story. See the BOM:538874 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexus Surgical and Medicare Ltd is involved in Importing and Marketing Quality Surgical and Pharmaceutical Products at an Economical Price. The Company is a wholesale dealer dealing in various sizes of disposal syringes (with and without needles) and pouches of various sizes used for the storage of sterilized equipment and materials. It operates in the segment of trading activities.
82GF Score
Get the complete analysis for BOM:538874
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538874 has been successfully added to your 
